| 000 | 01905 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517051550.0 | ||
| 264 | 0 | _c20161102 | |
| 008 | 201611s 0 0 eng d | ||
| 022 | _a1556-1380 | ||
| 024 | 7 |
_a10.1097/JTO.0000000000000671 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEng, Juliana | |
| 245 | 0 | 0 |
_aImpact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas. _h[electronic resource] |
| 260 |
_bJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer _cDec 2015 |
||
| 300 |
_a1713-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xdrug therapy |
| 650 | 0 | 4 | _aAdenocarcinoma of Lung |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aClass I Phosphatidylinositol 3-Kinases |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 |
_aErbB Receptors _xantagonists & inhibitors |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aPhosphatidylinositol 3-Kinases _xgenetics |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xtherapeutic use |
| 700 | 1 | _aWoo, Kaitlin M | |
| 700 | 1 | _aSima, Camelia S | |
| 700 | 1 | _aPlodkowski, Andrew | |
| 700 | 1 | _aHellmann, Matthew D | |
| 700 | 1 | _aChaft, Jamie E | |
| 700 | 1 | _aKris, Mark G | |
| 700 | 1 | _aArcila, Maria E | |
| 700 | 1 | _aLadanyi, Marc | |
| 700 | 1 | _aDrilon, Alexander | |
| 773 | 0 |
_tJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer _gvol. 10 _gno. 12 _gp. 1713-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/JTO.0000000000000671 _zAvailable from publisher's website |
| 999 |
_c25227036 _d25227036 |
||